Stocks › BCRX
BIOCRYST PHARMACEUTICALS INC
BCRX·Nasdaq·
United States·USD
$7.22
-0.10 (-1.37%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
BCRX
BIOCRYST PHARMACEUTICALS INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BCRXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of BCRX by members of U.S. Congress · 5 on record · 2 in the last 12 months
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Gilbert Ray Cisneros, Jr.House · D · CA |
BCRXBIOCRYST PHARMACEUTICALS INC · Stock |
Purchase $1,001 - $15,000 |
Sep 4, 2026 | Jul 10, 2026 | Filing ↗ |
Gilbert Ray Cisneros, Jr.House · D · CA |
BCRXBIOCRYST PHARMACEUTICALS INC · Stock |
Purchase $1,001 - $15,000 |
Dec 15, 2025 | Nov 13, 2025 | Filing ↗ |
Josh GottheimerHouse · D · NJ |
BCRXBIOCRYST PHARMACEUTICALS INC · Stock |
Purchase $1,001 - $15,000 |
Nov 11, 2023 | Oct 16, 2023 | Filing ↗ |
Josh GottheimerHouse · D · NJ |
BCRXBIOCRYST PHARMACEUTICALS INC · Stock |
Sale $1,001 - $15,000 |
Oct 15, 2023 | Sep 15, 2023 | Filing ↗ |
Josh GottheimerHouse · D · NJ |
BCRXBIOCRYST PHARMACEUTICALS INC · Stock |
Purchase $1,001 - $15,000 |
Sep 16, 2022 | Aug 11, 2022 | Filing ↗ |
Whale Activity
Position changes in BCRX reported for 2026-09-30 by 367 institutional filers
- Increased97
- New51
- Held50
- Decreased122
- Closed33
- No prior filing14
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 24.3M | $202.7M | increased |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 15.5M | $129.0M | increased |
| STATE STREET CORP | 12.3M | $102.4M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 11.3M | $93.9M | decreased |
| TCG Crossover Management, LLC | 11.0M | $91.8M | held |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 10.5M | $87.7M | decreased |
| PERCEPTIVE ADVISORS LLC | 10.3M | $85.8M | decreased |
| Janus Henderson Group Ltd. | 10.3M | $85.3M | — |
| TWO SIGMA INVESTMENTS, LP | 7.2M | $60.0M | increased |
| Jones Hill Capital LP | 7.1M | $59.0M | new |
| Aberdeen Group plc | 6.5M | $53.9M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 6.1M | $50.4M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by BCRX insiders, by quarter · Form 4
Recent Insider Transactions
1,044 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Stonehouse Jon PDirector | Grant / award | +644 | $9.70 | $6K | Aug 31, 2026 | Form 4 ↗ |
| Milne Jill C.Director | Grant / award | +1,288 | $9.70 | $12K | Aug 31, 2026 | Form 4 ↗ |
| MILANO VINCENTDirector | Grant / award | +1,159 | $9.70 | $11K | Aug 31, 2026 | Form 4 ↗ |
| McKee Amy EDirector | Grant / award | +644 | $9.70 | $6K | Aug 31, 2026 | Form 4 ↗ |
| Frank StevenDirector | Grant / award | +1,288 | $9.70 | $12K | Aug 31, 2026 | Form 4 ↗ |
| Milne Jill C.Director | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| Galson Steven KDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| LEVIN ALAN GDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| Frank StevenDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| SANDERS MACHELLEDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| MILANO VINCENTDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| Stonehouse Jon PDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| McKee Amy EDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| HEGGIE THERESADirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| Milne Jill C.Director | Grant / award | +1,262 | $8.91 | $11K | May 29, 2026 | Form 4 ↗ |
| Stonehouse Jon PDirector | Grant / award | +631 | $8.91 | $6K | May 29, 2026 | Form 4 ↗ |
| McKee Amy EDirector | Grant / award | +631 | $8.91 | $6K | May 29, 2026 | Form 4 ↗ |
| MILANO VINCENTDirector | Grant / award | +1,122 | $8.91 | $10K | May 29, 2026 | Form 4 ↗ |
| Frank StevenDirector | Grant / award | +1,262 | $8.91 | $11K | May 29, 2026 | Form 4 ↗ |
| McKee Amy EDirector | Sale | −11.2K | $8.97 | $100K | May 18, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding BCRX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 9.6M | $95.8M | 0.89% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 8.1M | $80.7M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 6.0M | $60.5M | 0.07% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.9M | $29.1M | 0.02% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.8M | $28.4M | 0.03% | Jun 30, 2026 |
| abrdn Healthcare Investors | 2.3M | $23.2M | 1.71% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 2.5M | $22.8M | 0.07% | Jul 31, 2026 |
| VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS | 2.3M | $22.6M | 0.19% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 2.1M | $21.5M | 0.14% | Jun 30, 2026 |
| abrdn Healthcare Opportunities Fund | 2.1M | $20.9M | 2.53% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list BCRX's shares (CUSIP 09058V103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- RA Capital Healthcare Fund, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Nov 16, 2026 · ↗ - Rajeev ShahSCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Nov 16, 2026 · ↗ - Peter KolchinskySCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Nov 16, 2026 · ↗ - RA Capital Management, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Nov 16, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 12.3M shares4.8%
Nov 10, 2026 · ↗ - RA Capital Healthcare Fund, L.P.SCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
Aug 14, 2026 · ↗ - Rajeev ShahSCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
Aug 14, 2026 · ↗ - Peter KolchinskySCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
Aug 14, 2026 · ↗ - RA Capital Management, L.P.SCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
Aug 14, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 15.2M shares6.0%
Aug 7, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming biocryst pharmaceuticals as client
No lobbying filings found naming BIOCRYST PHARMACEUTICALS INC as the client.
- BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2018 Q3$10K
Filing ↗ - BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2018 Q2$20K
Filing ↗ - BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2018 Q1 · MED, DIS$20K
Filing ↗ - BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2017 Q4 · DIS, MED$20K
Filing ↗ - BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2017 Q3 · MED, DIS$20K
Filing ↗
Government Contracts
Federal awards to biocryst pharmaceuticals · USAspending
$182KAwarded · 2 contracts on record
U.S. Patents
Recent USPTO applications naming BIOCRYST PHARMACEUTICALS INC
No USPTO patent applications found for BIOCRYST PHARMACEUTICALS INC.
Annual Financials
From BCRX's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | $341.0M | -$2.5M | -$103.7M | -$148.4M | -$177.7M |
| Net income | $263.9M | -$88.9M | -$226.5M | -$247.1M | -$184.1M |
| Diluted EPS | $1.21 | -$0.43 | -$1.18 | -$1.33 | -$1.03 |
| Operating cash flow | $347.4M | -$52.0M | -$95.1M | -$161.8M | -$142.2M |
| Cash and equivalents | $89.7M | $104.7M | $110.6M | $304.8M | $504.4M |
| Total assets | $514.2M | $490.4M | $517.0M | $550.0M | $588.2M |
| Total liabilities | $633.3M | $966.4M | $972.5M | n/a | n/a |
| Shareholders' equity | -$119.2M | -$475.9M | -$455.5M | -$294.6M | -$107.0M |
As BIOCRYST PHARMACEUTICALS INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in BCRX's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureNov 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureAug 5, 2026
EDGAR ↗ - 8-K/A · Items 2.05Exit or disposal costsAug 4, 2026
EDGAR ↗ - 8-K · Items 2.05, 7.01, 9.01Exit or disposal costs · Reg FD disclosureJun 29, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 12, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureMay 6, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureMay 4, 2026
EDGAR ↗
About BIOCRYST PHARMACEUTICALS INC
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersDURHAM, NC
IncorporatedDE
SEC CIK0000882796 ↗


